Abstract
Intracerebral haemorrhage (ICH) is caused by spontaneous, non-traumatic haemorrhage within the brain parenchyma. ICH has poor outcomes, with a 30-40% 1-month case fatality and most survivors remaining dependent. Current management of ICH is aimed at providing appropriate supportive care and reducing the risk of haematoma expansion, which affects up to 20-30% of patients in the first 24 hours. Rapid and intensive blood pressure lowering to a pre-specified target and reversal of anticoagulants in the 20% of patients who are taking them may reduce the risk of expansion and improve outcome.
Subject
Management, Monitoring, Policy and Law,Geography, Planning and Development
Reference44 articles.
1. Feigin VL, Stark BA, Johnson CO, Roth GA, Bisignano C, Abady GG, et al. Global, regional, and national burden of stroke and its risk factors, 1990-2019: a systematic analysis for the Global Burden of Disease Study 2019. Lancet Neurol. 2021 Oct 1;20(10):795-820.
2. Béjot Y, Grelat M, Delpont B, Durier J, Rouaud O, Osseby GV, et al. Temporal trends in early case-fatality rates in patients with intracerebral hemorrhage. Neurology. 2017 Mar 7;88(10):985-90. https://doi.org/10.1212/WNL.0000000000003681
3. Connolly SJ, Ezekowitz MD, Yusuf S, Eikelboom J, Oldgren J, Parekh A, et al. Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med. 2009 Sep 17;361(12):1139-51. https://doi.org/10.1056/NEJMoa0905561
4. Sprigg N, Flaherty K, Appleton JP, Salman RAS, Bereczki D, Beridze M, et al. Tranexamic acid for hyperacute primary IntraCerebral Haemorrhage (TICH-2): an international randomised, placebo-controlled, phase 3 superiority trial. The Lancet. 2018 May 26;391(10135):2107-15. https://doi.org/10.1016/S0140-6736(18)31033-X
5. Mayer SA, Brun NC, Begtrup K, Broderick J, Davis S, Diringer MN, et al. Efficacy and Safety of Recombinant Activated Factor VII for Acute Intracerebral Hemorrhage. N Engl J Med. 2008 May 15;358(20):2127-37. https://doi.org/10.1056/NEJMoa0707534